Skip CCR Main Navigation

By Bill Cole,2014-12-09 19:39
9 views 0
Skip CCR Main Navigation

    Skip CCR Main Navigation

    | Home | Search

    About CCR

    Our Patients

    Our Science

    Our News

    Fellowships & Positions ; Our Science

    ; Wayne Website

    ; Home

    ; Publications

    ; Gallery

    ; Staff

    ; Links

    ; Faculties

    ; POB Website

    ; Home

    ; Animal Resources

    ; Core Resources

    ; NCI-Frederick

Our Science Wayne Website

    Alan S. Wayne, M.D.

     Pediatric Oncology Branch

    Head, Hematologic Diseases Section

    Senior Clinician

    National Cancer Institute

    Building 10-CRC, Room 1W-3750

    9000 Rockville Pike

    Bethesda, MD 20892-1104

    301-496-4256 Phone:

    301-451-7010 Fax: E-Mail:


    Dr. Wayne received his M.D. from Northwestern University and carried out his residency and fellowship training at Children's Hospital and the Dana-Farber Cancer Institute in Boston. Past positions have included associate director of the blood bank at Boston Children's, director of transfusion medicine in the Division of Allergy/Immunology/Bone Marrow Transplantation at the University of South Florida/All Children's Hospital, and director of pediatric bone marrow transplantation at the University of Miami. In July 1999, Dr. Wayne joined the NCI as the clinical director of the Pediatric Oncology Branch (POB) and the head of the Hematologic Diseases Section. In addition, Dr. Wayne directs the Fellowship Training Program in Pediatric Hematology-Oncology, which became a joint program with Johns Hopkins University in 2000. Dr. Wayne is a diplomate of the American Board of Pediatrics Sub-Board of Pediatric Hematology/Oncology.


    The primary goal of the clinical research program of the Hematologic Diseases Section is to develop new treatment strategies for hematologic malignancies, the most frequent cancer type in pediatrics. Although cure rates are excellent for many subtypes of childhood leukemia and lymphoma, new approaches are needed to overcome resistance to standard therapies and to decrease treatment-associated

    sequelae in survivors of pediatric cancer. A major focus of the Hematologic Diseases Section research program is the development of targeted agents for childhood leukemias and lymphomas. A second area of investigation is the application of hematopoietic stem cell transplantation as a platform to direct allogeneic anti-tumor responses for pediatric leukemias, lymphomas, and sarcomas. Collaborative biologic correlative and pre-clinical studies are conducted as part of these trials. The Section has extensive collaborations with Intramural and Extramural Investigators.

    This page was last updated on 7/15/2008.

    Home | Contact Us | Policies | Accessibility | Viewing Files | Search |

    A service of the National Cancer Institute

Report this document

For any questions or suggestions please email